Bristol Myers Squibb Company (NYSE:BMY) to Issue Quarterly Dividend of $0.63

Bristol Myers Squibb Company (NYSE:BMY) declared a quarterly dividend on Monday, March 2nd. Shareholders of record on Thursday, April 2nd will be given a dividend of 0.63 per share by the biopharmaceutical company on Friday, May 1st. This represents a c) annualized dividend and a yield of 4.2%. The ex-dividend date is Thursday, April 2nd.

Bristol Myers Squibb has raised its dividend by an average of 0.0%annually over the last three years and has increased its dividend annually for the last 17 consecutive years. Bristol Myers Squibb has a dividend payout ratio of 41.5% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Bristol Myers Squibb to earn $6.09 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 41.4%.

Bristol Myers Squibb Stock Performance

Shares of Bristol Myers Squibb stock opened at $59.76 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. The company has a market cap of $122.01 billion, a PE ratio of 17.32, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The company has a 50 day moving average of $58.91 and a 200-day moving average of $52.35. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period last year, the business earned $1.67 earnings per share. The business’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts forecast that Bristol Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Bristol Myers Squibb

Several hedge funds have recently added to or reduced their stakes in BMY. J. Derek Lewis & Associates Inc. bought a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $432,000. Osbon Capital Management LLC bought a new position in shares of Bristol Myers Squibb during the fourth quarter valued at $55,000. World Investment Advisors lifted its holdings in shares of Bristol Myers Squibb by 14.1% during the fourth quarter. World Investment Advisors now owns 64,471 shares of the biopharmaceutical company’s stock worth $3,478,000 after purchasing an additional 7,977 shares during the period. Nalls Sherbakoff Group LLC bought a new stake in shares of Bristol Myers Squibb in the fourth quarter worth $92,000. Finally, Larry Mathis Financial Planning LLC acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at $427,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.